Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
Shadman M, Munir T, Ma S, Lasica M, Tani M, Robak T, Flinn IW, Brown JR, Ghia P, Ferrant E, Tam CS, Janowski W, Jurczak W, Xu L, Tian T, Lefebure M, Agresti S, Hirata J, Tedeschi A. Shadman M, et al. Among authors: ferrant e. J Clin Oncol. 2025 May 31:JCO2500758. doi: 10.1200/JCO-25-00758. Online ahead of print. J Clin Oncol. 2025. PMID: 40448577
Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN.
Sharman JP, Egyed M, Jurczak W, Skarbnik AP, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliato LM, Herishanu Y, Banerji V, Follows GA, Walker PA, Ghia P, Janssens AM, Byrd JC, Ferrant EF, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Palhares de Miranda PA, Munugalavadla V, Wun CC, Woyach JA. Sharman JP, et al. Among authors: ferrant ef. Blood. 2025 Apr 8:blood.2024024476. doi: 10.1182/blood.2024024476. Online ahead of print. Blood. 2025. PMID: 40198878
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Sharman JP, et al. Among authors: ferrant e. Leukemia. 2025 Feb;39(2):529. doi: 10.1038/s41375-024-02487-1. Leukemia. 2025. PMID: 39627506 Free PMC article. No abstract available.
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.
Sesques P, Karlin L, Massy E, Maarek A, Aussedat G, Lazareth A, Golfier C, Bouafia-Sauvy F, Lequeu H, Ghergus D, Safar V, Ferrant E, Bachy E, Ghesquières H, Confavreux CB, Demangel D, Perrial E, Dumontet C. Sesques P, et al. Among authors: ferrant e. Front Oncol. 2024 Oct 31;14:1436587. doi: 10.3389/fonc.2024.1436587. eCollection 2024. Front Oncol. 2024. PMID: 39544298 Free PMC article.
Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital.
Lan CL, Belot A, Golfier C, Audin B, Sesques P, Bernier A, Safar V, Ferrant E, Lazareth A, Lequeu H, Karlin L, Ghergus D, Maarek A, Aussedat G, Idlhaj M, Salles G, Cherblanc F, Bachy E, Ghesquieres H. Lan CL, et al. Among authors: ferrant e. Hematol Oncol. 2024 Jul;42(4):e3297. doi: 10.1002/hon.3297. Hematol Oncol. 2024. PMID: 38989917 Free PMC article. No abstract available.
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
Gazeau N, Beauvais D, Tilmont R, Srour M, Ferrant E, Safar V, Fouillet L, Flandrin-Gresta P, Gower N, Chauvet P, Duployez N, Podvin B, Demaret J, Huet S, Sujobert P, Ghesquières H, Damaj G, Bachy E, Morschhauser F, Yakoub-Agha I, Heiblig M, Sesques P. Gazeau N, et al. Among authors: ferrant e. Leukemia. 2025 Jul;39(7):1714-1722. doi: 10.1038/s41375-025-02605-7. Epub 2025 Apr 24. Leukemia. 2025. PMID: 40275069 Free PMC article.
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.
Bussot L, Poulain S, Nudel Ortmans M, Davi F, Roos-Weil D, Lepretre S, Richard D, Pastoret C, Desmares A, Ferrant E, Huet S, Sujobert P, Delabesse E, Ysebaert L, Lazarian G, Michallet AS, Bidet A, Dilhuydy MS, Delfau-Larue MH, Dupuis J, Clavert A, Drenou B, Maitre E, Troussard X, Cornet E, Le Bris Y, Lok A, Villemagne B, Barbier H, Béné MC, Tomowiak C, Tardy S, Cornillet-Lefebvre P, Quinquenel A, Guièze R, Barbieux S, Plantier I, Hieulle J, Gresta PF, Cornillon J, Dupire S, Laribi K, Feugier P, Algrin C, Lachenal F, Caillet A, Murati A, Inchiappa L, Lechat C, Dartigeas C, Montaut É, Molina L, Carras S. Bussot L, et al. Among authors: ferrant e. Leukemia. 2025 May;39(5):1247-1251. doi: 10.1038/s41375-025-02555-0. Epub 2025 Apr 1. Leukemia. 2025. PMID: 40169763 Free PMC article. No abstract available.
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.
Guièze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, Aurran T, Clavert A, de Guibert S, Michallet AS, Saad A, Drénou B, Quittet P, Hivert B, Laribi K, Gay J, Quinquenel A, Broseus J, Rouille V, Schwartz D, Magnin B, Lazarian G, Véronèse L, de Antonio M, Laurent C, Tournilhac O, Pereira B, Feugier P. Guièze R, et al. Among authors: ferrant e. Nat Commun. 2024 Aug 9;15(1):6822. doi: 10.1038/s41467-024-51264-2. Nat Commun. 2024. PMID: 39122717 Free PMC article. Clinical Trial.
54 results